Biotech Values

[oc631]

Given neck and neck trial results, there seems to be a possibility that ENTA gathers 62% and GILD enjoys 38%. Just thinking.

The highest market share within the U.S. that the ABBV combo could ever expect to attain is 45% since GILD has a more desirable combination. I personally feel 40% would be an incredible accomplishment and should be a goal set by the company through pricing and marketing strategy.